On March 10, 2025, Traws Pharma, Inc. entered into an At The Market Offering Agreement allowing it to sell up to $50 million in common stock through Citizens JMP Securities, LLC, with a commission of 3% on sales. The company is not obligated to sell any shares under this agreement.